Selective Inhibition of Thromboxane Synthetase Reduces Group-B-Beta-Hemolytic-Streptococci-Induced Pulmonary Hypertension in Piglets

Publisher Website
Google Scholar
Abstract
13 newborn piglets with group-B-.beta.-hemolytic-streptococci (GBS)-induced pulmonary hypertension were assigned to recieve either placebo (group 1) or Dazmegrel, a thromboxane synthetase inhibitor (group 2). All piglets with pulmonary hypertension had increased thromboxane B2 (TxB2)and 6-keto PGF1.alpha. levels. With continued GBS infusion, the placebo group demonstrated a continued elevation of pulmonary artery pressure (PAP) and of TxB2. The Dazmegrel piglets, however, despite continued GBS infusion, demonstrated a selective decrease in PAP associated with a significant decrease in TxB2 levels and stability of systemic pressure and cardiac output. These data demonstrate that thromboxane synthetase inhibition is effective therapeutically in selectively reducing PAP.